SEC For	m 4																				
	UNITE	s s	ECUR	OMMI	SSION		OMB	APPRO	VAL												
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					ENT OF CHANGES IN BENEFICIAL OWNE led pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											HIP	Estin	Numbe nated av s per res	erage burde	3235-0287 n 0.5	
1. Name and Address of Reporting Person* Glezer Eli N.						2. Issuer Name and Ticker or Trading Symbol <u>Singular Genomics Systems, Inc.</u> [OMIC]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) Chief Scientific Officer				wner	
(Last) (First) (Middle) 10931 N. TORREY PINES ROAD SUITE #100					3. Date of Earliest Transaction (Month/Day/Year) 03/04/2022																
(Street) LA JOLL	LA C	92037	4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				n			
(City) (State) (Zip)																					
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans. Date (Month/L					action	۱	2A. Deemed Execution Date, if any (Month/Day/Year		, 3. Transaction Code (Instr.		n [d (A) or	or 5. Amount of and 5) Securities Beneficially Owned Follo		Form	nership : Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	4	Amount		(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable a Expiration Date (Month/Day/Year)			le and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Amount s Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securiti Benefici Owned Followir Reporte	ve es ally ng d	y Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
				Co	ode \	v					Expiration Date		Title	Amo or Num Title of Sł			Transaction(s) (Instr. 4)				

(1)

Explanation of Responses:

\$7.<mark>5</mark>

1. The option shares vest and become exercisable in 48 equal monthly installments measured from March 4, 2022.

Remarks:

Employee Stock Option (right to

buy)

/s/ Dalen Meeter, Attorney-in-**Fact**

500,000

\$0.00

Common

Stock

03/04/2032

03/08/2022

500,000

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

03/04/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

500,000